Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации10023Conference ProceedingsTherapy of bevacizumab-induced arterial hypertension in the blood pressure variability paradigmKhlyamovStanislav Valerievich<p>Postgraduate student of the Department of Pharmacology, junior researcher at the Laboratory of Experimental Cardiopharmacology, Research Institute of Experimental Medicine</p>xavjelinell@yandex.ruhttps://orcid.org/0000-0001-8985-9599Kursk State Medical University271220241321381391604202411062024Copyright © 2024, Khlyamov S.V.2024<div> <p><em>Introduction. The topic of treatment of bevacizumab-induced arterial hypertension (AH) in the paradigm of blood pressure variability remains insufficiently studied. One of the reasons for this problem is the lack of sufficient research on the problem being studied. Target. To compare the effect of lercanidipine and fosinopril on blood pressure variability (BPV) after treatment of bevacizumab-induced hypertension. Materials and methods. A retrospective analysis was performed on 80 clinical cases of colorectal cancer using targeted chemotherapy with bevacizumab, which were accompanied by the development of hypertension. Clinical cases were divided into 2 groups: fosinopril group (n = 40, mean age - 53.68 12.24 years), lercanidipine group (n = 40, mean age - 56.24 14.51 years). Bevacizumab was administered at a dose of 7.5 mg/kg intravenously. BP was measured after 4 weeks of bevacizumab. Fosinopril and lercanidipine were prescribed at a dose of 4 and 5 mg per day, respectively. Dynamic parameters of systolic and diastolic blood pressure (SBP and DBP) were measured in the groups. The mean deviation and coefficient of variation (Cv) were taken as indicators of VAD. Results. An 8-week treatment with lercanidipine significantly reduced BP and VBP, while fosinopril had no significant effect on BP reduction in bevacizumab-induced hypertension. Conclusions. Systolic and diastolic VBP with lercanidipine in the treatment of arterial hypertension induced by bevacizumab is better than with fosinopril, and therefore lercanidipine can be recommended as a first-line drug in the treatment of bevacizumab-induced hypertension.</em></p> </div>bevacizumabcardio-oncologyarterial hypertensioncardiotoxicityblood pressure variabilityбевацизумабкардиоонкологияартериальная гипертензиякардиотоксичностьвариабельность артериального давления1.Чазова, И.Е. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022) / И.Е. Чазова, Ф.Т. Агеев, А.В. Аксенова [и др.] // Евразийский Кардиологический Журнал. - 2022. - №1. - С. 6-79.2.3.Химиотерапия онкологических заболеваний и риск развития кардиотоксического профиля на примере человеческого рекомбинированного моноклонального антитела бевацизумаб / С.В. Хлямов, Г.С. Маль, Е.Б. Артюшкова [и др.] // Innova. - 2023. - Т. 9. - №1. - С.52-59.4.5.Эффективность нефиксированных комбинаций антигипертензивной терапии при лечении бевацизумаб-индуцированной артериальной гипертензии у крыс линии Wistar / Гладченко М.П., Маль Г.С., Артюшкова Е.Б. [и др.] // Современные проблемы науки и образования. – 2023. – №4. - URL: https://science-education.ru/ru/article/view?id=32918 (дата обращения: 17.03.2024).